DNA sequencing reagents for the Illumina sequencing platforms

NOTICE OF INTENT TO SOLE SOURCE

The Centers for Disease Control and Prevention (CDC) is responsible for conducting acquisitions in support of the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).

NCEZID has a requirement entitled "DNA sequencing reagents for the Illumina sequencing platforms" which are needed for utilization in the laboratory along with the existing Illumina DNA sequencing platforms. No other vendor has been found which manufacturers these reagents since Illumina, Inc. is the sole manufacturer of these patented reagents. It has been found that Illumina, Inc. is the only manufacturer of the sequencer and associated modules and is the only source for reagents that are compatible with the DNA sequencing platforms in the genomic sequencing laboratory.

The CDC intends to award a sole-source order to Illumina, Inc. in order to satisfy the requirement. The authority for this action is Federal Acquisition Regulation (FAR) Subsection 13.106-1; in particular, only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization).

This notice of intent is not a request for competitive offers / quotations. This is only an opportunity to provide specific and convincing information that the requirement should instead be competed and the respective capabilities of the responder. All such responses received by the closing date / time of this notice will be considered by the government. A determination by the government whether or not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the government. Any quotation/response should be emailed to contract specialist Kari L. Skovira @ kuf5@cdc.gov by 4:00 p.m. EST on July 29, 2016.